A2A PharmaFeb 7, 20201 min readA2A / Daewoong Pharmaceutical Oncology Agreement A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery.LEARN MORE73 views0 comments
A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery.LEARN MORE
A2A co-founded biomea Fusion raises $56MBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of
A2A Appoints New AdvisorsDr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE
A2A Pharmaceuticals Appoints CEOA2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer LEARN MORE